|
OCUP | Opus Genetics, Inc. |
|
|
OCUP | Opus Genetics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.23 |
| Leverage | 83.48% |
| Market Cap | $ 25.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -67.7m |
| Margin | -362.65% |
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. The company is headquartered in Farmington Hills, Michigan.